Afaf Mikou Research Project

Afaf's research focuses on neurological diseases, especially Schizophrenia, which affects nearly 64 million people worldwide. Several studies have shown that, in the brain, the NMDA (N-methyl-D-aspartate) receptors are involved in memory and learning process and their hypofunction can be associated with Schizophrenia symptoms. Moreover, a direct activation of these receptors, with small therapeutic molecules, can generate strong side effects. To avoid this, Afaf’s research aims to target a new protein called the Asc-1 transporter. Indeed, this protein carries some specific amino acid (D-serine, glycine) which ensure the proper functioning of the NMDA receptor. Using molecular dynamics modelling, Afaf first built different models of the transporter and then simulated each step of the transport mechanism of the amino acids. This basic understanding is beginning to uncover new therapeutics avenues for restoring the normal functions of the Asc-1 transporter, and thus provide benefits for alleviating Schizophrenia symptoms.

Photo: The Asc-1 transporter - The structure of this protein was simulated using molecular modelling.